A news release about studies of ONC201, the founding member of a novel class of anti-cancer compounds called imipridones, quoted Vincent Cryns, MD, professor and head, Endocrinology, Diabetes and Metabolism and Marian A. and Rodney P. Burgenske Chair in Diabetes Research. 

The article described two preclinical studies by researchers at Fox Chase Cancer Center and Wayne State University, respectively, of ONC201 on triple-negative breast cancer human and mouse cell lines. 

"These preclinical studies provide further support for testing ONC201 in clinical trials, such as our recently funded phase II trial in metastatic triple-negative breast cancer, which will incorporate an innovative dietary intervention,” said Dr. Cryns.

The upcoming clinical study led by Dr. Cryns and Ruth O'Regan, MD, professor and head, Hematology, Medical Oncology and Palliative Care, will investigate a low-methionine diet in combination with ONC201 for triple-negative breast cancer (TNBC).

Resources:

• "Research Publications Provide Rationale For ONC201 Trials In Breast Cancer," BioSpace, May 9, 2017